Welcome to our dedicated page for Gilead Sciences SEC filings (Ticker: GILD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Gilead Sciences, Inc. (Nasdaq: GILD) is a Delaware‑incorporated biopharmaceutical company whose common stock is registered on The Nasdaq Global Select Market. As an SEC‑reporting issuer, Gilead files a range of regulatory documents that provide detailed insight into its financial condition, governance and material events. This page aggregates GILD’s SEC filings and pairs them with AI‑generated summaries to help readers understand the key points in complex disclosures.
For Gilead, Form 10‑K annual reports and Form 10‑Q quarterly reports are central sources of information on its HIV, viral hepatitis, COVID‑19, oncology and inflammation businesses, including segment discussions, risk factors and research and development spending. Form 8‑K current reports capture specific developments such as quarterly financial results, amendments to bylaws, executive leadership changes and significant agreements. Recent 8‑K filings, for example, have disclosed financial results for particular quarters, updates to the company’s bylaws governing director nominations and stockholder proposals, patent settlements related to Biktarvy, and changes in senior corporate affairs and legal roles.
Investors can also use this page to access proxy statements for information on board structure and executive compensation, and Form 4 insider transaction reports to track trades by directors and officers. Because Gilead is not classified as an emerging growth company, its filings follow the full disclosure requirements applicable to large, established issuers.
Stock Titan enhances GILD filings with AI‑powered explanations that highlight material items, translate technical accounting and legal language into plain terms, and surface topics such as governance changes, litigation updates or collaboration agreements. Real‑time ingestion from EDGAR means new Gilead filings appear quickly, while the AI layer helps readers focus on what changed, why it matters for the company’s HIV, antiviral and oncology franchises, and how it may affect shareholders.
Gilead Sciences executive reports stock award vesting. EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M acquired 470 shares of Gilead common stock on the reported date at a stated price of $0.00 per share, increasing directly held common stock to 4,414 shares.
The shares relate to specific tranches of performance share awards originally granted on March 10, 2025. These tranches were subject to both performance-vesting and service-vesting conditions, with the performance goals certified as attained by the Compensation and Talent Committee on the reported vesting date.
Gilead Sciences Chairman & CEO Daniel O'Day reported both an equity award and stock sales. He acquired 38,396 shares of common stock at $0.00 per share as part of performance share awards granted on March 10, 2025, which vested after the compensation committee certified performance goals.
On the same date, he sold a total of 10,000 common shares in open-market transactions at prices ranging from about $143.63 to $145.71, under a Rule 10b5-1 trading plan adopted on February 28, 2025. After these transactions, he directly held 642,308 shares of Gilead common stock.
Daniel O'Day reports proposed sales of GILD common stock under Form 144. The filing lists recent transactions including a sale of $17,346,000.00 for 115,640 shares on 02/05/2026, and earlier sales of 115,640 shares on 01/23/2026 for $15,611,400.00. The record also shows multiple 10,000-share transactions in late 2025 and January 2026 with corresponding proceeds listed.
Gilead Sciences is a large biopharmaceutical company focused on HIV, liver disease, COVID-19 and oncology, with a global presence in more than 35 countries. Its medicines include HIV regimens like Biktarvy and Descovy, liver treatments such as Epclusa and Vemlidy, COVID-19 therapy Veklury, and cell therapies Yescarta and Tecartus.
The company highlights a broad late‑stage pipeline in virology and oncology, including lenacapavir for HIV prevention, bulevirtide for hepatitis delta, and multiple CAR T and antibody‑drug conjugate programs. It emphasizes extensive patent protection, with key products such as Biktarvy and Veklury covered into the 2030s, and notes growing pricing and reimbursement pressures from U.S. policy changes like the Inflation Reduction Act, Medicaid and 340B rules, and international cost controls.
Gilead also describes significant manufacturing infrastructure in the U.S., Europe and Canada, reliance on contract manufacturers, and a workforce of about 17,000 employees. It stresses human capital, ESG priorities and detailed risk factors spanning competition, product demand volatility, regulatory change, climate rules and complex U.S. drug‑pricing reforms.
Gilead Sciences, through wholly owned Purchaser Ravens Sub, Inc., announced a proposed acquisition of Arcellx, Inc. The offer contemplates $115.00 per share in cash plus one contingent value right (CVR) that would pay $5.00 upon achievement of a specified milestone under a CVR agreement, pursuant to an Agreement and Plan of Merger dated February 22, 2026.
The tender offer has not commenced; the communication is a preliminary solicitation and states that final tender offer materials, including a Schedule TO and Arcellx’s Schedule 14D-9, will be filed with the SEC when the offer begins.
Gilead Sciences entered into a merger agreement to acquire Arcellx through a tender offer for $115 per share plus one contingent value right (CVR). The Offer will initially remain open for a minimum of 20 business days and is subject to customary closing conditions, including obtaining antitrust clearances.
The CVR entitles holders to $5.00 if cumulative worldwide sales of Arcellx’s anito-cel exceed $6,000,000,000 on or prior to December 31, 2029. Support agreements cover approximately 10.3% of outstanding shares as of February 19, 2026.
Gilead Sciences plans to acquire Arcellx through a tender offer for $115.00 per share in cash plus a $5.00 contingent value right (CVR) per share, implying equity value of $7.8 billion. Each CVR pays $5.00 in cash if cumulative worldwide sales of anitocabtagene autoleucel (anito-cel) reach $6.0 billion by December 31, 2029.
A Gilead subsidiary will launch a tender offer for all Arcellx shares it does not already own, needing more than 50% of outstanding shares, with customary antitrust and other closing conditions. Gilead currently owns about 11.5% of Arcellx, and support agreements cover an additional 10.3% of shares.
Following successful completion of the offer, Arcellx will merge into the Gilead subsidiary, and remaining shares will receive the same cash and CVR consideration. Anito-cel’s Biologic License Application for fourth-line relapsed or refractory multiple myeloma has been accepted by the FDA, with a Prescription Drug User Fee Act action date of December 23, 2026, and Gilead expects the deal to be accretive to earnings per share in 2028 and beyond upon FDA approval.
Gilead Sciences executive Johanna Mercier reported a mix of option exercises and stock sales. On February 17, 2026, she exercised 25,000 non-qualified stock options, acquiring 25,000 shares of common stock at $66.64 per share through a derivative exercise.
That same day, she sold 18,405 shares at $154.182, 9,395 shares at $154.9105, and 200 shares at $155.62 in open-market transactions under a Rule 10b5-1 trading plan adopted on February 20, 2025. After these transactions, she held 120,288 shares of common stock and 48,110 options directly.
Gilead Sciences Chief Financial Officer Andrew D. Dickinson sold 3,000 shares of common stock in an open-market transaction. The sale took place on February 17, 2026, at an average price of $154.43 per share. After this sale, he directly owned 167,779 shares. The transaction was made under a Rule 10b5-1 trading plan adopted on August 29, 2024, and the share balance also reflects purchases through the company’s Employee Stock Purchase Plan.
A person named Johanna Mercier has filed to sell up to 28,000 shares of the issuer’s common stock through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $4,324,227.70, on or about 02/17/2026 on the NASDAQ market.
The shares to be sold include 25,000 shares acquired via a stock option exercise for cash on 02/17/2026 and 3,000 restricted shares acquired on 03/10/2024. Over the prior three months, Mercier sold 3,000 shares on 01/15/2026 for $372,930.00 and another 3,000 shares on 12/15/2025 for $366,000.00.